TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03969277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
Study: NCT04073368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1957
Description: Amino acids, food study

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1125
Description: Amino acids, food study
Study: NCT00307593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab
Study: NCT01829035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Transarterial Chemoembolization (cTACE)
Description: Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed
Study: NCT00382096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Study: NCT04073368

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amino acids, food study
Study: NCT04245462

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study: NCT00900601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrodesis to the sacroiliac joint and symphysis
Description: Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery.
Study: NCT01825603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADH-1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03282565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training with Brace
Description: A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
Study: NCT02269735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin (RHI)
Description: RHI 100 units/mL intravenous infusion to maintain target glycemic level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin (RHI)
Description: RHI 100 units/mL intravenous infusion to maintain target glycemic level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin (RHI)
Description: RHI 100 units/mL intravenous infusion to maintain target glycemic level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin (RHI)
Description: RHI 100 units/mL intravenous infusion to maintain target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
Study: NCT03282565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training with Elastic Band
Description: An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
Study: NCT00905216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin sodium - Bergamo
Description: 5.000 UI/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium - APP
Description: 5.000 USP
Study: NCT00359918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrinolysis
Description: Primary PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: Primary PCI
Study: NCT01770652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator
Study: NCT02298985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 3 g/day (3 capsules/day) for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: 3 g/day (3 capsules/day) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 3 g/day (3 capsules/day) for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 g/day (3 capsules/day) for 6 months
Study: NCT04121988

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: 1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging
Study: NCT01288027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alglucosidase Alfa
Description: Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
Study: NCT00795925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propiverine hydrochloride
Description: coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d.
Study: NCT04134702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
Study: NCT00700570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv on day 1 of each 2 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85mg/m2 iv on day 1 of each 2 week cycle
Study: NCT02441400

Intervention type: DEVICE
Intervention: EndoStim LES Stimulation System
Study: NCT02269735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
Study: NCT04362644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Description: Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
Study: NCT02269735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
Study: NCT04070040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
Study: NCT00090064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
Study: NCT01262209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable CCTV
Description: This is a small handheld mini screen intended to improve reading.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescopes, telemicroscopes and microscopes
Description: These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
Study: NCT00090064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose placebo pill
Description: 125 mg followed by a supplemental half-dose of 62.5 mg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy provided by a team of two co-therapists

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy provided by a team of two co-therapists
Study: NCT03829501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1044
Description: A human anti-ICOS monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1044
Description: A human anti-ICOS monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1044 and atezolizumab
Description: A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1044 and atezolizumab
Description: A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)
Study: NCT01262209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorptive filters
Description: These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
Study: NCT01013298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-guided PCT
Description: extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
Study: NCT02360111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT00089856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with allogeneic prostate vaccine
Description: Immunotherapy with allogeneic prostate vaccine

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Taxotere and prednisone)
Description: Chemotherapy (Taxotere and prednisone)
Study: NCT03507062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% saline administration
Description: Each patient will receive 0.9%saline based on attending physician decision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ringer's lactate administration
Description: Each patient will receive Ringer's lactate based on attending physician decision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmalyte-like solution administration
Description: Each patient will receive Plasmalyte-like solution based on attending physician decision
Study: NCT00382096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin + Metformin
Study: NCT04119037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cordotomy
Description: Undergo cordotomy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine
Description: Given via injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo fake cordotomy
Study: NCT03849144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy dog activity
Description: Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low impact exercise
Description: The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
Study: NCT02615275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioelectric Impedance Analysis
Description: Undergo BIA with seca mBCA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT03819426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise Intervention
Description: Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Intervention
Description: Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
Study: NCT02269735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
Study: NCT03600298

Intervention type: OTHER
Group type: OTHER
Intervention: Simulation
Description: Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
Study: NCT02269735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
Study: NCT01356979

Intervention type: PROCEDURE
Intervention: Medical thoracoscopy
Description: Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
Study: NCT03590834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-based Intervention
Description: 1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks
Study: NCT03969277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Cold application around the elbow joint for 15 minutes in every session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Application
Description: Cold application around the elbow joint for 15 minutes in every session.
Study: NCT00202397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: capsule-shaped 50 mg tablets bid for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule-shaped tablet bid for 8 weeks
Study: NCT01068652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000-2000 mg/day in combination with insulin treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000-2000 mg/day in combination with insulin treatment
Study: NCT03491306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
Study: NCT02615275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT01543230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System